Gilbert – The Sanford Guide to Antimicrobial Therapy 52 Ed. 2022

¡¡DISPONIBLE!!

TABLA DE CONTENIDO:

Coverage includes:

• Clinical syndromes
  • pathogens
  • bacterial
  • fungal
  • mycobacterial
  • parasitic
  • viral
• Anti-infective agents
  • dosing
    • pediatric adjustments
    • renal adjustments
  • adverse effects
  • activity
  • pharmacology
  • interactions
• Preventative therapy

What’s new in 2022:
Numerous changes throughout, with major changes in the following areas:

• New Drugs – Addition of new COVID-19 drugs, cefiderocol, ibrexafungerp, brincidofovir, cabotegravir, doravirine, and more.
• New Tables – ECMO Drug Dosing Adjustment (Table 10F) and QTc Prolongation (Table 10G).
• Table 1: Initial Choice of Antimicrobial Therapy – Numerous changes including 2021 CDC STI updates, recommendations for resistant infections.
• Table 5: Recommendations for MDR Bacteria – Updates for gram-negative bacilli updated based on recent evidence and IDSA Guidelines.
• Table 12: Treatment of Mycobacterial Infections – Revised recommendations for latent M. tuberculosis & non-tuberculous mycobacteria.
• Table 13: Treatment of Parasitic Infections – Significant changes to amebic meningoencephalitis, babesiosis and trypanosomiasis, and updates to sources for antiparasitic drugs (Table 13D).
• Table 14: Treatment of Viral Infections – Updates to COVID-19 treatment recommendations (digital subscriptions have most recent updates)